Claims for Patent: 10,030,270

Summary for Patent: 10,030,270

Title:	K-ras mutations and anti-EGFr antibody therapy
Abstract:	The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
Inventor(s):	Freeman; Daniel (Newbury Park, CA), Juan; Todd (Newbury Park, CA), Radinsky; Robert (Thousand Oaks, CA)
Assignee:	AMGEN, INC (Thousand Oaks, CA)
Application Number:	13/523,174
Patent Claims:	1. A method of treating a patient with metastatic colorectal cancer comprising determining the presence of a K-ras mutation in a tumor of the patient, said K-ras mutation selected from G13A and T20M, by (i) amplifying at least one K-ras nucleic acid from the tumor using a primer pair specific for at least one K-ras mutation selected from G13A and T20M, wherein said primer pair comprises one primer comprising SEQ ID NO: 19 and a second primer comprising SEQ ID NO: 20; and (ii) sequencing the amplified nucleic acid, wherein if neither of the K-ras mutations are present, administering to the patient an effective amount of panitumumab. 2. The method of claim 1, wherein the K-ras mutation is G13A. 3. The method of claim 1, wherein the K-ras mutation is T20M.

Details for Patent 10,030,270

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2027-03-13